Publication: D-penicillamine Induced Myasthenia Gravis in Wilson’s Disease: A Case Report
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Nepal Medical Association
Abstract
Abstract
Myasthenia gravis is a neuromuscular junction disorder characterised by fluctuating muscle weakness, improved by using anti-cholinesterase drugs. In addition to the autoimmune aetiology, various factors such as infections, surgery, and drugs are known to precipitate the condition. We report a case of a 15-year-old boy with D-penicillamine-induced myasthenia gravis who presented with facial diplegia, dysphagia, and drooling of saliva, 6 years after the initiation of treatment for Wilson’s disease. Therefore, clinicians should be more vigilant while prescribing patients with chelating drugs like D-penicillamine with regular monitoring of the new symptoms and keeping a very low threshold for the suspicion of myasthenia gravis.
Description
Lekhjung Thapa
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Monika Thapa
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Suman Bhattarai
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Abhishek Man Shrestha
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Nooma Sharma
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Nilshan Rai
KIST Medical College and Teaching Hospital, Imadol, Lalitpur, Nepal
Merina Pokharel
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Raju Paudel
Department of Neurology, National Neuro Center, Maharajgunj, Chakrapath, Kathmandu, Nepal
Keywords
D-penicillamine, Myasthenia gravis, Pyridostigmine, Wilson's disease